Targeting MTAP Loss in Pancreatic and Biliary Tract Cancers: Can It Fulfill the Promise?

Default Digital Object Group 2026 Dataset

View at publisher
DOI: 10.1200/adn.26.300308
Cited by: 0

Abstract

In pancreatic and biliary tract cancers, MTAP loss defines a clear therapeutic vulnerability, and early clinical studies with PRMT5 and MAT2A inhibitors show signals of clinical activity with acceptable safety profiles. Until more data are available, targeting MTAP-deleted cancers remains a promising but unproven strategy for these hard-to-treat cancers.

Publication details

Journal / source
Default Digital Object Group
Publication date
7 January 2026
Document type
Dataset